By Deena Beasley CHICAGO (Reuters) – Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that 29 out of 129 patients with 12 different types of advanced cancers responded to drugs targeting genetically driven abnormalities. The drugs were administered outside of indications currently approved by the U.S. Food and Drug Administration, which generally reviews drugs using studies based on the type of organ where the cancer was found.
View post:
Study finds targeted cancer drugs may work in range of tumor types
